^
    Apply
    Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma (NCT04901702)
    Phase 1/2
    St. Jude Children's Research Hospital
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    06/09/2021
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    EWSR1 • FLI1
    |
    temozolomide • Talzenna (talazoparib) • Onivyde (nanoliposomal irinotecan)
    Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease (NCT06023641)
    Phase 1/2
    St. Jude Children's Research Hospital
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    03/13/2024
    Primary completion :
    10/01/2034
    Completion :
    10/01/2037
    TP53 • FOXO1 • MYOD1
    |
    TP53 mutation
    |
    temozolomide • cyclophosphamide • vincristine • vinorelbine tartrate • dactinomycin • Onivyde (nanoliposomal irinotecan) • Navelbine oral (vinorelbine tartrate oral) • Neupogen (filgrastim)
    Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors (NCT04890093)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    10/31/2024
    Primary completion :
    02/28/2026
    Completion :
    12/31/2026
    UGT1A1
    |
    UGT1A1*28 • UGT1A1*1*1
    |
    temozolomide • vincristine • locnartecan (PEN-866)
    A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma (ARST2031) (NCT04994132)
    Phase 3
    Children's Oncology Group
    Active, not recruiting
    Last update posted :
    02/18/2025
    Initiation :
    09/14/2021
    Primary completion :
    09/30/2027
    Completion :
    09/30/2027
    FOXO1
    |
    cyclophosphamide • vincristine • dactinomycin • Navelbine oral (vinorelbine tartrate oral)
    VITAS: Atezolizumab in Combination with Chemotherapy for Pediatric Relapsed/refractory Solid Tumors (NCT04796012)
    Phase 1/2
    University of Texas Southwestern Medical Center
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    04/18/2023
    Primary completion :
    01/01/2027
    Completion :
    01/01/2027
    PD-L1
    |
    Tecentriq (atezolizumab) • temozolomide • irinotecan • vincristine
    Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma (NCT05304585)
    Phase 3
    Children's Oncology Group
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    08/04/2022
    Primary completion :
    06/30/2030
    Completion :
    06/30/2030
    FOXO1
    |
    cyclophosphamide • vincristine • dactinomycin
    Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) (NCT03155620)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/04/2025
    Initiation :
    07/31/2017
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    BRAF
    |
    Lynparza (olaparib) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Vitrakvi (larotrectinib) • Koselugo (selumetinib) • Balversa (erdafitinib) • Retevmo (selpercatinib) • Ensacove (ensartinib) • Zarnestra (tipifarnib) • Tazverik (tazemetostat) • ulixertinib (BVD-523) • samotolisib (LY3023414)
    Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma (ARST1431) (NCT02567435)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/04/2025
    Initiation :
    06/01/2016
    Primary completion :
    06/30/2023
    Completion :
    10/16/2025
    FOXO1 • PAX3 • PAX7
    |
    cyclophosphamide • irinotecan • temsirolimus • vincristine • vinorelbine tartrate • dactinomycin
    Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) (NCT03213704)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/04/2025
    Initiation :
    08/23/2017
    Primary completion :
    09/30/2024
    Completion :
    10/08/2025
    NTRK
    |
    NTRK fusion
    |
    Vitrakvi (larotrectinib)
    Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors (PEPN2112) (NCT05071209)
    Phase 1/2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/03/2025
    Initiation :
    12/22/2021
    Primary completion :
    09/30/2024
    Completion :
    11/22/2025
    BRCA1 • BRCA2 • ATM • MSH2 • CDK12 • WT1 • ATRX • CHEK2 • RAD51 • FANCA • POLD1 • FOXO1 • XRCC2 • ATF1 • PAX3
    |
    PAX3-FOXO1 fusion
    |
    elimusertib (BAY 1895344)
    International PPB/DICER1 Registry (NCT03382158)
    Phase N/A
    Children's Hospitals and Clinics of Minnesota
    Recruiting
    Last update posted :
    01/30/2025
    Initiation :
    12/06/2016
    Primary completion :
    12/06/2030
    Completion :
    12/06/2035
    DICER1
    |
    doxorubicin hydrochloride • cyclophosphamide
    Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma (TARGET-RT) (NCT06796543)
    Phase N/A
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Not yet recruiting
    Last update posted :
    01/29/2025
    Initiation :
    03/01/2025
    Primary completion :
    03/01/2028
    Completion :
    03/01/2030
    EFS